fda aod9604 approval status AOD-9604 Clinical Trial Results & (2026) BPC-157 FDA Approval Status 2026:

However, it is essential to distinguish between the known biological roles of each ingredient and the unproven claim that injecting them together produces clinically meaningful fat loss

While AOD 9604 offers a safer and potentially cost-effective approach with added joint health benefits, Semaglutide stands out as the most effective option for significant weight loss, supported by robust clinical research

Cant C, et al

Initial correction of significant deficiency typically involves weekly or biweekly injections for several weeks until levels normalize and symptoms resolve

In the Phase 2b trial (2007, n=536) AOD-9604 showed weight reduction only 0.3 kg greater than placebo after 24 weeks